Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botensilimab + Nab-paclitaxel + Gemcitabine in Metastatic Pancreatic Cancer
NCT05630183Phase 2Completed
- Sponsor
- Agenus Inc.
- Start
- Mar 2023
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of botensilimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Agenus Inc.. Started Mar 2023; status: completed.
02
Drugs
botensilimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05630183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630183.